Press Release
Diversity in Cancer Clinical Trials
“I think it’s important to ensure that you consider each person uniquely. Because no matter how much I know or the nurse knows about the population, everybody is a little bit different. It’s really important to personalize every approach and ask them what they know and meet them where they are,” ONS member Reneé Kurz, DNP, RN, FNP-BC, AOCNP®, director of clinical research operations at Rutgers Cancer Institute of New Jersey in New Brunswick, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS, during a conversation about increasing diversity in clinical trials.
Related Topics
You May Also Like
Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
Introducing OncologyVoiceNetwork.com
Article
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast